Drug shows promise for triple-negative breast cancer

July 3, 2012
Tulane scientists, led by Dr. Bridgette Collins-Burow, have reported research results of a promising new therapy for triple-negative breast cancer. (Photo by Paula Burch-Celentano)

(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by Dr. Bridgette Collins-Burow.

More than one million cases of are diagnosed worldwide every year, of which approximately 15 percent are triple-negative cancers, according to the team that reported on the study.

“Lack of effective therapies, young age at the onset of the disease and early metastatic spread have contributed to the poor prognoses and outcomes associated with these malignancies,” says Collins-Burow, an assistant professor of medicine.

Some kinds of breast cancer can be treated with drugs that target hormone receptors, which are protein structures on and inside cells. In healthy cells and most kinds of cancer cells, hormones attach to such receptors and provide signals to the cells for growth and functioning.

These cancers can be treated by hormonal therapies — drugs that bind to the receptors in place of hormones, thus cutting off hormonal signaling and eventually killing the cells.

But triple-negative breast cancers lack these hormone receptors, so the cancer cells continue to flourish. Triple-negative cancers also lack the growth factor receptor HER2 and cannot be treated with monoclonal therapy such as Herceptin. 


The Tulane team explored the effect of using a histone deacetylase (HDAC) inhibitor called panobinostat on triple-negative breast cancer tumors in mice. This drug inhibits the actions of rogue enzymes that are responsible for allowing the uncontrolled growth of cancer cells. 


“Panobinostat selectively targeted triple-negative breast and decreased tumor growth in mice,” says Collins-Burow. “It was also able to partially reverse the morphological changes in cells to a more epithelial type. These results show a potential therapeutic role for HDAC inhibitors, especially panobinostat, in targeting the aggressive triple-negative breast cancer.”

Explore further: Blocking DNA: HDAC inhibitor targets triple negative breast cancer

More information: breast-cancer-research.com/content/14/3/R79

Related Stories

Blocking DNA: HDAC inhibitor targets triple negative breast cancer

May 21, 2012
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research. Researchers ...

Breaking the backbone of triple-negative breast cancers

March 19, 2012
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.

Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells

November 1, 2011
Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells – knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor ...

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.